FINWIRES · TerminalLIVE
FINWIRES

Thermo Fisher Likely to Benefit From End-Market Recovery, but Structural Risks Remain, RBC Says

By

Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a report emailed Friday.

"Investor skepticism" surrounding Thermo Fisher's 2026 guidance and broader post-pandemic recovery trends "is well-founded" after several years of uneven "normalization" across the life sciences tools industry, RBC noted. Still, the firm said recovery prospects appear "more plausible" as uncertainty in large pharmaceutical and academic markets begin to ease.

The firm said normalized organic growth closer to 5% may be as likely as management's 7%-plus target and the Wall Street's roughly 6% forecast. It also pointed to "lingering" artificial intelligence uncertainty surrounding the long-term outlook for the company's contract research organization business, which represents about 20% of sales, according to the report.

RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target.

Price: $442.17, Change: $-6.04, Percent Change: -1.35%

Related Articles

Wire

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD
Wire

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH
Wire

KinderCare Learning Q1 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

KinderCare Learning (KLC) reported Q1 adjusted earnings late Thursday of $0.04 per diluted share, down from $0.23 a year earlier.Analysts surveyed by FactSet expected a loss of $0.01.Revenue in the three months ended April 4 rose to $672.5 million from $668.2 million a year earlier.Analysts surveyed by FactSet expected $669.1 million.The company boosted full-year adjusted EPS guidance to $0.15 to $0.25 from the previous forecast of $0.10 to $0.20. It affirmed the revenue outlook of $2.7 billion to $2.75 billion.Analysts expect EPS of $0.15 on revenue of $2.71 billion.KinderCare shares fell 6.2% in after-hours trading.

$KLC